These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 10613094)

  • 21. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.
    Carpentier PJ; de Jong CA; Dijkstra BA; Verbrugge CA; Krabbe PF
    Addiction; 2005 Dec; 100(12):1868-74. PubMed ID: 16367988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stimulants for ADHD in child patients with Tourette's syndrome: the issue of relative risk.
    Gadow KD; Sverd J
    J Dev Behav Pediatr; 1990 Oct; 11(5):269-71; discussion 272. PubMed ID: 1979565
    [No Abstract]   [Full Text] [Related]  

  • 23. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?
    Killeen MR
    J Child Fam Nurs; 2000; 3(1):46-8. PubMed ID: 11022478
    [No Abstract]   [Full Text] [Related]  

  • 24. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications.
    Varley CK; Vincent J; Varley P; Calderon R
    Compr Psychiatry; 2001; 42(3):228-33. PubMed ID: 11349243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Letter to the editor: Comment on 'Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder'.
    Olders H
    J Pediatr Psychol; 2009; 34(1):108-9; author reply 110-2. PubMed ID: 19136567
    [No Abstract]   [Full Text] [Related]  

  • 26. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse.
    Kuczenski R; Segal DS
    Biol Psychiatry; 2005 Jun; 57(11):1391-6. PubMed ID: 15950013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects.
    Leonard BE; McCartan D; White J; King DJ
    Hum Psychopharmacol; 2004 Apr; 19(3):151-80. PubMed ID: 15079851
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.
    Biederman J
    J Clin Psychiatry; 2003; 64 Suppl 11():3-8. PubMed ID: 14529323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.
    Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM
    J Clin Psychopharmacol; 2007 Oct; 27(5):459-67. PubMed ID: 17873677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults.
    Faraone SV; Biederman J; Wilens TE; Adamson J
    Psychol Med; 2007 Dec; 37(12):1743-52. PubMed ID: 17349106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flawed attention-deficit/hyperactivity disorder medication comparison.
    Adesman A
    Pediatrics; 2004 Oct; 114(4):1132; author reply 1132-3. PubMed ID: 15466129
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of methylphenidate on EEG coherence in attention-deficit/hyperactivity disorder.
    Clarke AR; Barry RJ; McCarthy R; Selikowitz M; Johnstone SJ; Abbott I; Croft RJ; Magee CA; Hsu CI; Lawrence CA
    Int J Psychophysiol; 2005 Oct; 58(1):4-11. PubMed ID: 15921774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylphenidate transdermal system.
    Mays DA; Findling R
    J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1223. PubMed ID: 16292112
    [No Abstract]   [Full Text] [Related]  

  • 35. [Methylphenidate induced ST elevation acute myocardial infarction].
    Ruwald MH; Ruwald AC; Tønder N
    Ugeskr Laeger; 2012 Mar; 174(10):647-8. PubMed ID: 22395014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular effects of methylphenidate.
    Daniels SR
    J Pediatr; 2009 Jul; 155(1):A3. PubMed ID: 19559283
    [No Abstract]   [Full Text] [Related]  

  • 37. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: a retrospective case-control study of rheumatology patients.
    Goldman W; Seltzer R; Reuman P
    Arthritis Rheum; 2008 Feb; 58(2):563-6. PubMed ID: 18240233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attention deficit hyperactivity disorder and substance use disorders.
    Szobot CM; Bukstein O
    Child Adolesc Psychiatr Clin N Am; 2008 Apr; 17(2):309-23, viii. PubMed ID: 18295148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transdermal methylphenidate (Daytrana) for ADHD.
    Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.